Related Experiment Videos
Sulfasalazine-induced agranulocytosis
The American Journal of Gastroenterology
|February 1, 1985
Summary
Sulfasalazine can cause agranulocytosis, a dangerous drop in white blood cells, in ulcerative colitis patients. Early detection of fever or illness during the first two months of treatment is crucial for prompt intervention.
Area of Science:
- Gastroenterology
- Hematology
- Pharmacology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Sulfasalazine is a common treatment for UC, but can have adverse effects.
- Agranulocytosis is a rare but serious side effect characterized by a severe reduction in granulocytes.
Observation:
- A patient with UC developed agranulocytosis 5 weeks after starting sulfasalazine.
- Symptoms included fever, skin rash, and severe myeloid hypoplasia on bone marrow examination.
- Antineutrophil antibodies were notably absent.
Findings:
- Recovery commenced within two weeks, marked by a leukemoid reaction and thrombocytosis.
- The patient tolerated 5-aminosalicylate enemas subsequently, indicating a potential alternative.
- Agranulocytosis from sulfasalazine typically manifests within the first two months of therapy.
Implications:
- This case highlights the importance of monitoring for agranulocytosis in UC patients on sulfasalazine.
- Prompt evaluation of unexplained fever or illness during early treatment is essential.
- Identifying rare adverse drug reactions is critical for patient safety and treatment optimization.